BS

Biosig Technologies IncNASDAQ BSGM Stock Report

Last reporting period 31 Mar, 2024

Updated 24 Oct, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

BSGM Stock Analysis

BS

Uncovered

Biosig Technologies Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-52/100

Low score

Market cap $B

0.006

Dividend yield

Shares outstanding

48.02 B

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. The company is headquartered in Westport, Connecticut and currently employs 50 full-time employees. The company went IPO on 2014-09-22. The firm is focused on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and cardiac catheter ablation procedures for atrial fibrillation (AF) and ventricular tachycardia (VT). The firm is commercializing its PURE EP System, which is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials. PURE EP is a signal processing platform that combines hardware and software to address known challenges associated with signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time. The device aims to minimize noise and artifacts from cardiac recordings and acquire high-fidelity cardiac signals.

View Section: Eyestock Rating